Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


18F-FDG PET predicts lymphoma treatment outcome


A new and somewhat controversial study published in the August issue of the Journal of Nuclear Medicine suggests that 18F-FDG PET results obtained after the first cycle of treatment can better predict progression-free survival in patients with aggressive non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD) than PET scans conducted at the end of treatment.

Physicians at the Weill Medical College of Cornell and the New York Presbyterian Hospital in New York reported on 23 patients who received PET scans before and after one cycle of treatment and also at the completion of chemotherapy. PET was accurate 87% of the time after one cycle but only 70% of the time after completion of chemotherapy. Sensitivity, i.e., the ability to detect the FDG and hence disease, was also significantly higher after one cycle, at 82% v. 45.5%. In particular, in cases in which results from the first cycle differed from the results following completion of therapy, the results from the first cycle scan were more accurate. Ninety percent of patients with positive 18F-FDG PET results after one cycle experienced disease relapse, while 85% who had negative 18F-FDG PET findings after one cycle remained in remission. The authors concluded that PET was a better predictor of outcome and response to therapy after just one cycle of chemotherapy than after completion.

PET stands for positron emission tomography. Because of its unique ability to measure metabolic activity–or the efficiency of the cells converting food to energy--PET provides accurate, noninvasive detection and staging of many cancers. A radiopharmaceutical, such as 18F-FDG (fluorodeoxyglucose), which includes a radionuclide (a radioactive element) is injected into the patient and gives off signals that are measured by a PET scanner. Because cancer cells are more metabolically active, they show up on the PET images more intensely than normal tissue.

Using 18F-FDG PET to predict outcomes and response to therapy early in treatment is one of the most important new uses of this technology. It is particularly helpful in lymphoma, where tumors can persist after successful treatment. Conventional imaging with CT or MRI has difficulty differentiating between residual masses harboring tumor and those that are scar tissue. Determining at what point during chemotherapy a PET study should be ordered is a major issue in the nuclear medicine community. Debate continues regarding the timing of and access to this procedure.

The study also looked specifically at the results for patients whose diagnosis or original staging placed them in the category of poor-prognosis, and found similar results for this group. According to the study authors, 18F-FDG PET may be especially useful for these patients, since early evidence of persistent disease may mandate innovative intervention such as bone marrow transplantation.

The study reported a statistically significant number of false negatives in patients who had completed treatment, which contributed to its lower value as a predictor at the end of treatment. Six patients who had a false-negative FDG uptake at the completion of treatment ultimately relapsed. The authors noted that this could be the result of small amounts of disease that remained and escaped detection because of the resolution limitations of the coincidence PET scanner used in the study.

In a commentary accompanying the article in JNM, Val Lowe, MD and Gregory Wiseman, MD, of the Department of Radiology at the Mayo Clinic took issue with parts of the study’s findings, and elements of the study makeup. While commending the authors’ objectives, Lowe and Wisemen noted that the use of a coincidence rather than dedicated full-ring PET camera, which has less sensitivity, could have affected the results, particularly as they related to end-of-cycle findings of disease. They pointed to studies that showed dedicated PET at the completion of therapy had a 91% sensitivity in predicting disease relapse (v. the 45.5% in the Kostakoglu study). Nevertheless, the study authors emphasize the fact that failure to achieve a response can be predicted just after one cycle of therapy at which time second-line therapy or stem cell transplantation can be considered earlier prior to completing the full course of chemotherapy, without patients experiencing unnecessary side effects.

Lowe and Wiseman also expressed concerns about the size and makeup of the study group, noting that there were only 30 patients enrolled (the study report focuses on 23). The fact that it was a small study looking at different diseases, being treated differently, and at different points in their treatments make it difficult to make meaningful comparisons, they felt. According to the American Cancer Society, there will be an estimated 60,900 new cases of lymphoma in 2002, including 7,000 cases of Hodgkin’s disease and 53,900 cases of non-Hodgkin’s lymphoma. An estimated 25,800 people will die from the disease (24,400 NHL, 1400 HD)

"PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease" was written by Lale Kostakoglu, MD, Division of Nuclear Medicine, Department of Radiology; Morton Coleman, MD, and John P. Leonard, MD, Center for Lymphoma and Myeloma, Division of Hematology and Oncology, Department of Medicine; Ichiei Kuji, MD, Holly Zoe, and Stanley J. Goldsmith, MD, Division of Nuclear Medicine, Department of Radiology, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, New York.

Copies of the article and images related to the study and the commentary are available to media upon request to Karen Lubieniecki at, (703) 683-0357. Copies of this and past issues of The Journal of Nuclear Medicine are available online at Print copies can be obtained at $15 per copy by contacting the SNM Service Center, Society of Nuclear Medicine, 1850 Samuel Morse Drive, Reston, VA 20190-5315; phone: (703) 326-1186; fax: (703) 708-9015; e-mail: A yearly subscription to the journal is $170. A journal subscription is a member benefit of the Society of Nuclear Medicine.

Karen Lubieniecki | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

TRAPPIST-1 planets provide clues to the nature of habitable worlds

21.03.2018 | Physics and Astronomy

The search for dark matter widens

21.03.2018 | Materials Sciences

Natural enemies reduce pesticide use

21.03.2018 | Life Sciences

Science & Research
Overview of more VideoLinks >>>